Aaron Fortney, MD
Ophthalmology · Bismarck, NDNPI 1447297189
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $579 of the $794 with a category attached, or 72.9%. 10 manufacturers reported payments, led by Alcon at 32.7% of the total. Reporting peaked in 2019 at $245 and has fallen 66.3% since, to $83 in 2025.
Across 25 payments — averaging $31.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$260
- Carl Zeiss Meditec USA, Inc.$215
- AbbVie$87
- Omeros Corporation$63
- The Cameron-ehlen Group, Inc.$60
- Novartis$28
- plus $82 from 4 others
What the payments were for
- Food & beverage$57973%
- Other$21527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $260 |
| Carl Zeiss Meditec USA, Inc. | 1 | $215 |
| AbbVie(2 entities) | 4 | $87 |
| Omeros Corporation | 5 | $63 |
| The Cameron-ehlen Group, Inc. | 1 | $60 |
| Novartis | 2 | $28 |
| Sight Sciences, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA 700$215
How this compares
$794 in reported general payments places this provider in the 55th percentile of 41 ophthalmology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 58 | $22,694 |
| RestasisCyclosporine | 22 | $21,859 |
| CombiganBrimonidine Tartrate/Timolol | 55 | $14,298 |
| Travoprost | 62 | $11,189 |
| Latanoprost | 394 | $8,113 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $7,074 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $7,039 |
| AzoptBrinzolamide | 18 | $6,477 |
| Prednisolone Acetate | 99 | $6,002 |
| Cyclosporine | 14 | $4,861 |
| IlevroNepafenac | 12 | $4,575 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,817 |
| Brinzolamide | 14 | $3,815 |
| Fluorometholone | 32 | $3,004 |
| Timolol Maleate | 179 | $2,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $87 | $58,850135 claims |
| AlconAzopt, Simbrinza | $260 | $10,29535 claims |
| NovartisIlevro | $28 | $4,57512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 41 ophthalmology providers in North Dakota.
Other ophthalmology in Bismarck
- Andrew RodenburgBismarck$1K
- Paul SelidBismarck$1K
- Monte LeidenixBismarck$1K
- Elena RaducuBismarck$944
- Reid MollmanBismarck$869
- Douglas LitchfieldBismarck$862
- Charles VolkBismarck$0
- Michael GreenwoodWest Fargo$500K
- Lance BergstromFargo$10K
- Jennifer OlbumFargo$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.